VBI Vaccines Inc/BC
VBIVDelisted Sep 6, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000764195
VBI Vaccines Inc/BC was delisted on Sep 6, 2024; its insiders filed their last Form 4 on Jul 31, 2023; 41 institutions reported holding it in 13F filings for Q2 2024, worth $1.79M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by VBI Vaccines Inc/BC insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for VBI Vaccines Inc/BC, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| DeWilde Michel | Director | – | Jul 31, 2023 | 0 |
| Braga Damian | Director | – | Jul 31, 2023 | 0 |
| Gillis Steven | Director | 1,043,292Indirect | Jul 28, 2023 | 0 |
| Himes Vaughn B | Director | – | Jul 28, 2023 | 0 |
| Baxter Jeff | CEO, President | – | Jul 28, 2023 | 0 |
| Anderson David Evander | Chief Scientific Officer | – | Jul 28, 2023 | 0 |
| McKee Blaine H. | Director | – | Jul 28, 2023 | 0 |
| Diaz-Mitoma Francisco | Chief Medical Officer | – | Jul 28, 2023 | 0 |
| Beattie Nell | CFO, Head of Corp. Development | 68,200 | Jul 28, 2023 | 0 |
| Mazaltov Avi | Head Global MFG&GM-SciVac Ltd. | – | Jul 28, 2023 | 0 |
| Cordeiro Joanne | Director | – | Jul 28, 2023 | 0 |
| Dillman John Robert | Chief Commercial Officer | – | Jul 28, 2023 | 0 |
| Edelman Joseph | 10% Owner | 41,440,729Indirect | Apr 6, 2023 | 0 |
| Perceptive Advisors LLC | 10% Owner | 41,440,729Indirect | Apr 6, 2023 | 0 |
| Perceptive Life Sciences Master Fund Ltd | 10% Owner | 41,440,729Indirect | Apr 6, 2023 | 0 |
| McNulty Christopher | CFO and Head of BD | – | Jan 30, 2023 | 0 |
| Bain Linda | Director | – | Jan 31, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 18, 2023 (view filing) | Jul 10 | 8 daysLate | Gillis StevenDirector | PPurchaseCommon Shares, no par value per share | +609.1K | $1.65 | +$1.00M | +140.3%1.04M after | |
| Jul 18, 2023 (view filing) | Jul 10 | 8 daysLate | Gillis StevenDirector | PPurchase | −609.1K | – | – | –609.1K after | Derivative |
| Apr 6, 2023 (view filing)5:51 PM ET | Apr 4-6 | 2 days | Edelman Joseph and 2 others10% Owner | SSale | −10.9M | $0.1354 | −$1.48M | −20.8%41.4M after | 3 lots |
| Dec 6, 2021 (view filing) | Dec 3 | 3 days | Beattie NellChief Business Officer | PPurchaseCommon Shares, no par value per share | +8.20K | $2.45 | +$20.1K | +13.7%68.2K after | |
| Dec 3, 2021 (view filing)6:22 PM ET | Dec 1 | 2 days | Edelman Joseph and 2 others10% Owner | SSale | −2.71M | $3.31 | −$8.96M | −4.9%52.3M after |